Legend Biotech Corp (LEGN) SEC Filings, Jun-Jul 2026

The filing is a Form 144 notice regarding proposed sales of American Depositary Shares. The excerpt lists a broker (Fidelity Brokerage Services LLC) and a proposed sale quantity of 3,000 ADS with an associated figure of $88,800.00. The record also shows multiple prior restricted stock vesting events totaling 3,000 ADS on specific vesting dates.

Legend Biotech Corp Chief Executive Officer Ying Huang reported a disposition of ordinary shares tied to equity compensation taxes. On June 25, 2026, 5,566 ordinary shares were sold at a weighted average price of $14.78 per share, based on converted ADS prices.

According to the disclosure, these shares were sold to satisfy withholding tax obligations upon the vesting of restricted share units, making this a compensation-related, non-discretionary event rather than a typical open-market sale. Following the transaction, Huang directly holds 241,872 ordinary shares of Legend Biotech.

LEGN filed a Form 144 proposing the sale of 2,783 American Depositary Shares. The filing lists the shares as from a Restricted Stock Vesting event with a record date of 06/22/2026. The notice references $79,016.88 on the same line and lists execution via Fidelity Brokerage Services LLC on 06/26/2026.

The filing also discloses a prior disposition by Ying Huang of 4,968 American Depositary Shares on 03/26/2026 with a figure of $87,149.15 shown. The securities are listed for trading on NASDAQ.

Legend Biotech Corporation launched an underwritten public offering of 7,700,000 American Depositary Shares (ADSs), each representing two ordinary shares, at $29.35 per ADS. All ADSs are being sold by the company under its effective shelf registration.

The company expects net proceeds of approximately $211.6 million after underwriting discounts and expenses, assuming the underwriters do not exercise their option. The underwriters also have a 30-day option to buy up to 1,155,000 additional ADSs. The offering is expected to close on June 23, 2026, subject to customary conditions.

Legend Biotech Corporation is offering 7,700,000 American Depositary Shares (ADSs), each representing two ordinary shares, at an initial public offering price of $29.35 per ADS. The offering represents 15,400,000 ordinary shares and includes an underwriters’ option to purchase up to 1,155,000 additional ADSs. Net proceeds are estimated at approximately $211.6M before expenses (or approximately $243.5M if the option is exercised in full).

The company intends to use proceeds to fund pipeline development, including LB2501, for working capital and general corporate purposes. Combined with existing cash and cash equivalents as of March 31, 2026, Legend expects funding through the fourth quarter of 2027 under its current operating plan.

Legend Biotech Corporation is offering $225,000,000 of American Depositary Shares (ADSs) in a primary offering, with each ADS representing two ordinary shares. The ADSs trade on Nasdaq under the symbol LEGN; the prospectus cites 371,479,583 ordinary shares outstanding as of March 31, 2026 and a historical net tangible book value of $966.0 million (equivalent to $2.61 per ordinary share or $5.22 per ADS). The prospectus identifies use of proceeds for pipeline development including LB2501, working capital and general corporate purposes and discloses typical underwriting arrangements, lock-up restrictions and regulatory risk factors for PRC-based issuers.

Legend Biotech reported first-in-human proof-of-concept data for LB2501, an in vivo CD19/CD20 dual-targeting CAR-T therapy, in relapsed or refractory B-cell non-Hodgkin lymphoma. In an ongoing Phase 1 trial, a single infusion at the higher dose level achieved a 100% objective response rate and an 83.3% complete response rate, with all responses ongoing at data cutoff. Across 12 patients treated at two dose levels, overall objective response was 50.0% and complete response was 41.7% in a heavily pretreated population. LB2501 generated dose-dependent in vivo CAR-T expansion without lymphodepletion and showed a favorable safety profile, with no dose-limiting toxicities, serious adverse events, ICANS, or deaths, and only Grade 1–2 infusion reactions and cytokine release syndrome. Pharmacokinetic and translational data showed rapid vector clearance, T-cell–specific transduction, highly polyclonal integration, and persistent CAR-T detection, supporting clinical proof-of-concept for Legend’s in vivo TaVec platform.

Legend Biotech filed a Form 6-K highlighting early Phase 1 data for LB2501, an investigational in vivo CD19/CD20 dual‑targeting CAR-T therapy for relapsed/refractory B‑cell non-Hodgkin lymphoma. LB2501 is given as a single intravenous infusion without ex vivo cell manufacturing or lymphodepleting chemotherapy.

As of April 1, 2026, 12 patients were treated across two dose levels. At dose level 2, the objective response rate was 100% (6 of 6 patients), with a complete response rate of 83.3% (5 of 6), and all responses were ongoing at cutoff. Safety data showed no dose-limiting toxicities, serious adverse events, deaths, or immune effector cell-associated neurotoxicity; infusion reactions occurred in 75% of patients and cytokine release syndrome in 66.7%, all Grade 1–2. Pharmacokinetic data confirmed dose-dependent in vivo CAR-T expansion with cells detectable in blood for up to 116 days.

Legend Biotech reported new clinical data at ASCO 2026 for its investigational solid-tumor CAR-T LB2102 and for its approved multiple myeloma CAR-T, CARVYKTI®.

In an early Phase 1 study in relapsed or refractory small cell lung cancer or large-cell neuroendocrine carcinoma, LB2102 showed an objective response rate of 20% (4/20) and a disease control rate of 70% (14/20). At higher dose levels, responses improved to an objective response rate of 28.6% and disease control rate of 78.6%, with median disease control of 6.1 months and median duration of response of 6.5 months. Safety was described as manageable, with cytokine release syndrome in 30% of patients (all Grade ≤2) and ICANS in 15%.

For CARVYKTI®, new CARTITUDE-4 subgroup analyses showed progression-free and overall survival benefits across high-risk and standard-risk patients who responded to bridging therapy, with 30‑month overall survival rates above 85%. Additional pooled data described a low incidence of IEC-associated enterocolitis (1.2%) and detailed known serious risks such as CRS, neurologic toxicities, infections, prolonged cytopenias, secondary malignancies, and other adverse events, while CARVYKTI® remains approved and commercially available in 18 countries and has been used in more than 10,000 patients.